Indonesia vs United States of America: Previously treated cases tested for RR-/MDR-TB
Indonesia
83.0%
in 2024
United States of America
83.0%
in 2023
Indonesia rank
104th
United States of America rank
104th
Previously treated cases tested for RR-/MDR-TB over time
- Indonesia
- United States of America
How they compare
Indonesia currently reports 83.0% against 83.0% in United States of America, a difference of 0.0%.
The two have swapped places 5 times across 11 shared years of data; in 2013 it was United States of America ahead.
Indonesia ranks 104th and United States of America ranks 104th of 180 countries.
Indonesia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Indonesia | United States of America | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 86.6% | 70.6% | 16.0% | Indonesia |
| 2020s | 84.8% | 84.8% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Indonesia or United States of America?
- Indonesia, at 83.0% against 83.0% in United States of America as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Indonesia and United States of America?
- 0.0%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and United States of America?
- 11 years are reported by both, from 2013 to 2023.
- How do Indonesia and United States of America rank globally for previously treated cases tested for rr-/mdr-tb?
- Indonesia ranks 104th and United States of America ranks 104th of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.